A broad rally in vaccine stocks helped BioNTech clinch its best day in six years. That momentum may not last. U.S.-listed shares of the German biotech surged 22% to $113.12 on Wednesday for their ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BioNTech's pipeline setback shouldn't have completely surprised investors. The independent Data Safety Monitoring Board (DSMB) for the Phase 2 study of autogene cevumeran concluded in October 2025 ...
CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries ...
The company is working on several other promising candidates, including a combined coronavirus and flu vaccine, an HSV vaccine, and various cancer vaccines. True, BioNTech recently stopped a phase 2 ...
Novo Nordisk and Eli Lilly say GLP-1 drugs slowed aging clocks, but the data are early and unreviewed. Here is what patients should know. Had Gestational Diabetes or Postpartum Depression? Large Study ...
BioNTech has increased its previous revenue guidance and now expects its revenues for the full 2025 financial year to be in the range of €2,600 - €2,800 million. With regards to COVID-19 vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results